查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1488665

腫瘤轉錄組學市場 - 全球產業規模、佔有率、趨勢、機會和預測，按腫瘤類型、技術、產品、應用、最終用戶和地區細分，2019-2029F

Tumor Transcriptomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tumor Type, By Technology, By Product, By Application, By End User, and By Region, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球腫瘤轉錄組學市場估值為56.7 億美元，預計在預測期內將強勁成長，到2029 年複合年成長率為6.34%。見證顯著的成長。腫瘤轉錄組學涉及腫瘤細胞內基因表現模式的研究，為癌症生物學、進展和治療反應提供寶貴的見解。這個新興市場的特點是存在大量創新技術和平台，包括新一代定序 (NGS)、微陣列分析和定量聚合酶鍊式反應 (qPCR)。這些工具使研究人員和臨床醫生能夠分析基因表現水平、識別生物標記並闡明與各種癌症類型相關的分子途徑。推動腫瘤轉錄組學市場成長的主要驅動力之一是對精準腫瘤學解決方案的需求不斷成長。透過破解腫瘤複雜的分子特徵，醫療保健提供者可以為個別患者量身定做治療方案，最佳化治療效果，同時最大限度地減少不良反應。此外，新型生物資訊演算法和資料分析工具的出現徹底改變了資料解釋，促進將複雜的基因組資料轉化為臨床上可行的見解。尖端技術和計算方法的融合有望重新定義癌症診斷、預後和治療，最終徹底改變全球患者護理模式。隨著人口結構變化和生活方式因素的推動，全球癌症負擔持續升級，腫瘤轉錄組學在腫瘤學研究和臨床實踐中的重要性有望飆升。透過對研發的持續投資，加上學術界、工業界和醫療保健部門的協作努力，全球腫瘤轉錄組學市場有望持續擴張，在對抗癌症方面有望實現突破性創新和變革性成果。

市場概況
預測期 2025-2029
2023 年市場規模 56.7億美元
2029 年市場規模 81.2億美元
2024-2029 年複合年成長率 6.34%
成長最快的細分市場 乳癌
最大的市場 北美洲

主要市場促進因素

基因組技術的進步

對個人化醫療的需求不斷成長

癌症發生率和盛行率增加

主要市場挑戰

數據複雜性與解釋

標準化和可重複性

主要市場趨勢

單細胞轉錄組學

液體切片技術

細分市場洞察

腫瘤類型見解

技術洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球腫瘤轉錄組學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依腫瘤類型（乳癌、肺癌、大腸癌、攝護腺癌、黑色素瘤等）
    • 按技術（微陣列、即時定量、聚合酶鍊式反應 (Q-PCR)、其他）
    • 按產品（消耗品、儀器、軟體及服務）
    • 按應用（診斷和疾病分析、藥物發現、其他）
    • 按最終用戶（生物技術和製藥公司、研究和學術機構、其他） 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按腫瘤類型
    • 依技術
    • 按產品分類
    • 按申請
    • 按最終用戶
    • 按地區

第 6 章：亞太地區腫瘤轉錄組學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按腫瘤類型
    • 依技術
    • 按產品分類
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 7 章：歐洲腫瘤轉錄組學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按腫瘤類型
    • 依技術
    • 按產品分類
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：北美腫瘤轉錄組學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按腫瘤類型
    • 依技術
    • 按產品分類
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 英國
    • 加拿大
    • 墨西哥

第 9 章：南美洲腫瘤轉錄組學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按腫瘤類型
    • 依技術
    • 按產品分類
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲腫瘤轉錄組學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按腫瘤類型
    • 依技術
    • 按產品分類
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球腫瘤轉錄組學市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • Thermo Fischer Scientific, Inc.
  • Caris Life Sciences
  • Illumina, Inc.
  • NanoString Technologies, Inc.
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Standard BioTools Inc.
  • Pacific Biosciences of California, Inc

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 11739

Global Tumor Transcriptomics Market was valued at USD 5.67 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 6.34% through 2029. The Global Tumor Transcriptomics Market is witnessing a remarkable surge in growth, fueled by advancements in genomic research and personalized medicine. Tumor transcriptomics involves the study of gene expression patterns within tumor cells, offering invaluable insights into cancer biology, progression, and treatment responses. This burgeoning market is characterized by a plethora of innovative technologies and platforms, including next-generation sequencing (NGS), microarray analysis, and quantitative polymerase chain reaction (qPCR). These tools enable researchers and clinicians to profile gene expression levels, identify biomarkers, and elucidate molecular pathways implicated in various cancer types. One of the primary drivers propelling the growth of the tumor transcriptomics market is the increasing demand for precision oncology solutions. By deciphering the intricate molecular signatures of tumors, healthcare providers can tailor therapies to individual patients, optimizing treatment efficacy while minimizing adverse effects. Moreover, the advent of novel bioinformatics algorithms and data analytics tools has revolutionized data interpretation, facilitating the translation of complex genomic data into clinically actionable insights. This convergence of cutting-edge technologies and computational approaches is poised to redefine cancer diagnostics, prognostics, and therapeutics, ultimately revolutionizing patient care paradigms worldwide. As the global burden of cancer continues to escalate, fueled by demographic shifts and lifestyle factors, the significance of tumor transcriptomics in oncology research and clinical practice is poised to soar. With ongoing investments in research and development, coupled with collaborative efforts across academia, industry, and healthcare sectors, the Global Tumor Transcriptomics Market is poised for sustained expansion, promising groundbreaking innovations and transformative outcomes in the fight against cancer.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 5.67 Billion
Market Size 2029USD 8.12 Billion
CAGR 2024-20296.34%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

Key Market Drivers

Advancements in Genomic Technologies

Advancements in genomic technologies have revolutionized the landscape of cancer research and clinical practice, particularly within the realm of tumor transcriptomics. Next-generation sequencing (NGS), considered a cornerstone technology, has enabled high-throughput sequencing of tumor genomes and transcriptomes at unprecedented speeds and resolutions. NGS platforms offer comprehensive insights into the molecular mechanisms underlying cancer development, progression, and treatment responses by profiling gene expression patterns and detecting genomic alterations with unparalleled accuracy. Microarray analysis, another pivotal genomic technology, facilitates the simultaneous interrogation of thousands of genes within tumor samples, allowing researchers to characterize gene expression profiles and identify biomarkers associated with different cancer subtypes and disease states. Additionally, quantitative polymerase chain reaction (qPCR) technologies provide sensitive and precise quantification of gene expression levels, offering valuable validation and verification of transcriptomic findings. Moreover, advancements in single-cell transcriptomics technologies have emerged as a powerful tool for dissecting the heterogeneity of tumor cells, uncovering rare subpopulations, and elucidating dynamic transcriptional changes within the tumor microenvironment. These technological innovations have paved the way for more accurate cancer diagnostics, prognostics, and personalized treatment strategies, driving the Global Tumor Transcriptomics Market forward. The integration of genomic technologies with advanced bioinformatics and data analytics tools further enhances the interpretation and translation of complex genomic data into clinically actionable insights, fostering collaborations between academia, industry, and healthcare sectors to accelerate the pace of discovery and innovation in cancer research and therapy. As these technologies continue to evolve, they hold immense promise for revolutionizing our understanding of cancer biology and improving patient outcomes worldwide.

Rising Demand for Personalized Medicine

The rising demand for personalized medicine is profoundly shaping the landscape of the Global Tumor Transcriptomics Market. Personalized medicine aims to tailor medical treatments to the individual characteristics of each patient, including their genetic makeup, molecular profile, and lifestyle factors. In oncology, personalized medicine holds immense promise for optimizing treatment outcomes while minimizing adverse effects, driving the adoption of tumor transcriptomics technologies. Tumor transcriptomics plays a pivotal role in personalized medicine by elucidating the molecular signatures of tumors and identifying specific genetic alterations and expression patterns associated with cancer subtypes and disease progression. By analyzing the transcriptomic profiles of tumors, healthcare providers can identify actionable biomarkers and therapeutic targets unique to each patient, guiding treatment decisions towards more effective and targeted interventions. The integration of tumor transcriptomics data with other omics technologies, such as genomics, proteomics, and metabolomics, further enhances the precision and predictive power of personalized medicine approaches. This multi-omics approach enables comprehensive molecular profiling of tumors, facilitating the development of tailored treatment regimens based on the individual molecular characteristics of each patient's cancer. As the field of personalized medicine continues to advance, fueled by technological innovations and research breakthroughs, the demand for tumor transcriptomics technologies is expected to escalate further. By enabling the delivery of tailored therapies that address the specific molecular drivers of cancer, tumor transcriptomics is poised to play a central role in driving the future of personalized oncology care, ultimately improving patient outcomes and revolutionizing cancer treatment paradigms worldwide.

Increasing Cancer Incidence and Prevalence

The escalating incidence and prevalence of cancer globally have underscored the urgent need for innovative approaches to cancer diagnosis, treatment, and management, thereby driving the growth of the Global Tumor Transcriptomics Market. Factors such as population growth, aging demographics, and lifestyle changes have contributed to the rising burden of cancer worldwide. As a result, there is a growing imperative to develop more effective and targeted therapeutic strategies to address the diverse spectrum of cancer types and subtypes. Tumor transcriptomics offers a powerful tool for understanding the molecular mechanisms underlying cancer development, progression, and treatment responses. By analyzing the gene expression patterns and molecular signatures of tumors, researchers can identify novel biomarkers, therapeutic targets, and molecular pathways implicated in cancer pathogenesis. This deeper understanding of tumor biology enables the development of precision oncology approaches that aim to tailor treatments to the unique molecular characteristics of each patient's cancer. The integration of tumor transcriptomics with other omics technologies, such as genomics, proteomics, and metabolomics, enables a comprehensive molecular profiling of tumors, facilitating the discovery of personalized treatment regimens and predictive biomarkers. As the incidence and prevalence of cancer continue to rise, fueled by demographic shifts and lifestyle factors, the demand for tumor transcriptomics technologies is expected to grow, driving innovation and transformative advancements in cancer research and clinical practice.

Key Market Challenges

Data Complexity and Interpretation

Data complexity and interpretation pose significant challenges in the Global Tumor Transcriptomics Market, hindering the effective utilization of transcriptomic data for cancer research and clinical applications. Tumor transcriptomics generates vast datasets comprising gene expression profiles, alternative splicing events, and non-coding RNAs, presenting challenges in data processing, analysis, and interpretation. The sheer volume and complexity of transcriptomic data require sophisticated bioinformatics tools and computational algorithms to identify biologically meaningful patterns and extract actionable insights. Moreover, transcriptomic data are inherently noisy and subject to various sources of variability, including biological heterogeneity, technical artifacts, and sample-specific factors. Ensuring the accuracy and reliability of data interpretation is crucial for distinguishing true signal from background noise and minimizing false discoveries. Additionally, integrating transcriptomic data with other omics datasets, such as genomics, proteomics, and metabolomics, further complicates data interpretation, requiring advanced statistical methods and multi-dimensional analysis approaches. Addressing the challenges of data complexity and interpretation in tumor transcriptomics requires interdisciplinary collaboration between bioinformaticians, biostatisticians, computational biologists, and domain experts. Standardizing experimental protocols, data analysis pipelines, and quality control measures is essential to ensure the reproducibility and comparability of results across different studies and laboratories. Moreover, developing user-friendly software tools and databases for data visualization, mining, and knowledge discovery can empower researchers and clinicians to unlock the full potential of transcriptomic data in advancing cancer research and precision oncology.

Standardization and Reproducibility

Standardization and reproducibility are crucial challenges facing the Global Tumor Transcriptomics Market, impacting the reliability and comparability of transcriptomic data across different studies and laboratories. The lack of standardized experimental protocols, sample processing techniques, and data analysis pipelines contributes to variability and inconsistency in transcriptomic results, hindering translational research and clinical validation efforts. Establishing standardized protocols and quality control measures is essential to ensure the reproducibility and reliability of transcriptomic data. This includes standardizing procedures for sample collection, RNA extraction, library preparation, sequencing, and data analysis. Implementing quality control metrics and reference standards can help monitor and minimize technical variability, ensuring data integrity and robustness. Moreover, promoting data sharing and collaboration through initiatives such as the Global Alliance for Genomics and Health (GA4GH) and the Cancer Genome Atlas (TCGA) facilitates the development of standardized data formats, metadata standards, and analysis pipelines. These collaborative efforts aim to harmonize transcriptomic data generation and analysis practices, enabling cross-study comparisons and meta-analyses to derive more robust and generalizable insights into cancer biology. Addressing the challenges of standardization and reproducibility in tumor transcriptomics requires concerted efforts from researchers, funding agencies, regulatory bodies, and industry stakeholders. By establishing clear guidelines, best practices, and quality assurance frameworks, the Global Tumor Transcriptomics Market can overcome these challenges and advance towards more reliable and reproducible transcriptomic profiling for cancer research and precision oncology applications.

Key Market Trends

Single-Cell Transcriptomics

Single-cell transcriptomics is a cutting-edge technology revolutionizing cancer research within the Global Tumor Transcriptomics Market. Traditionally, bulk tumor transcriptomics provided valuable insights into average gene expression profiles across heterogeneous cell populations. However, it failed to capture the intricacies of cellular diversity and functional heterogeneity within tumors. Single-cell transcriptomics enables the high-resolution profiling of individual tumor cells, uncovering rare cell populations, spatial organization, and dynamic transcriptional states within the tumor microenvironment. This approach offers unprecedented insights into tumor heterogeneity, revealing distinct cell types, subpopulations, and transcriptional programs implicated in cancer progression, metastasis, and therapeutic resistance. By dissecting the molecular landscape of tumors at the single-cell level, researchers can identify novel biomarkers, therapeutic targets, and signaling pathways driving tumorigenesis and treatment responses. Moreover, single-cell transcriptomics facilitates the development of personalized treatment strategies by tailoring therapies to the unique molecular characteristics of individual patients' tumors. By deciphering the transcriptional signatures of rare cell populations and therapy-resistant clones, clinicians can optimize treatment regimens and improve patient outcomes. As single-cell transcriptomics technologies continue to advance, with improvements in sensitivity, throughput, and scalability, they hold immense promise for revolutionizing cancer diagnostics, prognostics, and precision oncology approaches within the Global Tumor Transcriptomics Market..

Liquid Biopsy Technologies

Liquid biopsy technologies are emerging as a transformative tool within the Global Tumor Transcriptomics Market. Unlike traditional tissue biopsies, liquid biopsies involve the non-invasive analysis of tumor-derived biomarkers, including circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), and cell-free DNA (cfDNA), present in bodily fluids such as blood, urine, and cerebrospinal fluid. Liquid biopsies offer several advantages over conventional tissue biopsies, including their minimally invasive nature, ability to capture tumor heterogeneity, and real-time monitoring of treatment responses and disease progression. In the context of the Global Tumor Transcriptomics Market, liquid biopsy technologies enable the profiling of tumor-specific transcripts and gene expression patterns in circulation, providing valuable insights into cancer biology and therapeutic responses. Transcriptomic analysis of ctRNA extracted from liquid biopsies allows for the detection and monitoring of tumor-associated gene expression signatures, such as oncogenes, tumor suppressor genes, and drug resistance markers. These transcriptomic profiles can inform treatment decisions, predict treatment responses, and identify actionable targets for personalized therapies. Moreover, liquid biopsy-based transcriptomic profiling holds promise for early cancer detection, minimal residual disease monitoring, and longitudinal surveillance of treatment efficacy and disease recurrence. As liquid biopsy technologies continue to evolve and become more accessible, they are poised to revolutionize cancer diagnostics, prognostics, and precision oncology approaches within the Global Tumor Transcriptomics Market.

Segmental Insights

Tumor Type Insights

Based on tumor type, breast cancer segment dominated the Global Tumor Transcriptomics Market in 2023. This is ascribed due due to its high incidence, diverse molecular subtypes, and clinical heterogeneity. Transcriptomic profiling enables comprehensive characterization of breast tumors, guiding personalized treatment strategies based on individual gene expression patterns and molecular signatures. Moreover, the integration of transcriptomic data with other omics datasets facilitates biomarker discovery, therapeutic target identification, and predictive modeling, driving advancements in breast cancer research and precision oncology initiatives. This emphasis on transcriptomic analysis empowers clinicians to optimize treatment decisions, improve patient outcomes, and address the complex biology of breast cancer effectively.

Technology Insights

Based on technology, microarray segment dominated the Global Tumor Transcriptomics Market in 2023. This is ascribed due to its established technology, cost-effectiveness, and high throughput. Microarray platforms allow for simultaneous analysis of thousands of genes, providing comprehensive gene expression profiling in tumor samples. Moreover, microarrays are versatile and suitable for various sample types, including formalin-fixed paraffin-embedded (FFPE) tissues and archived specimens. Despite competition from newer technologies like next-generation sequencing (NGS), microarrays remain widely used in research and clinical settings, offering a reliable and accessible option for transcriptomic analysis in cancer research and diagnostics.

Regional Insights

North America leads the Global Tumor Transcriptomics Market, due to several factors. The region boasts advanced healthcare infrastructure, robust research funding, and a highly skilled workforce. Additionally, the presence of key market players, academic institutions, and research centers accelerates innovation and technology adoption. Moreover, supportive regulatory frameworks and a strong emphasis on personalized medicine initiatives further drive the growth of tumor transcriptomics in North America. These factors collectively contribute to the region's leading position in the global market.

Key Market Players

Thermo Fischer Scientific, Inc.

Caris Life Sciences.

Illumina, Inc.

NanoString Technologies, Inc.

10x Genomics, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche AG

Standard BioTools Inc.

Pacific Biosciences of California, Inc

Report Scope:

In this report, the Global Tumor Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tumor Transcriptomics Market, By Tumor Type:

    Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Melanoma Others

Tumor Transcriptomics Market, By Technology:

    Microarray Real-Time Quantitative Polymerase Chain Reaction (Q-PCR) Others

Tumor Transcriptomics Market, By Product:

    Consumables Instrument Software & Services

Tumor Transcriptomics Market, By Application:

    Diagnostics and Disease Profiling Drug Discovery Others

Tumor Transcriptomics Market, By End User:

    Biotechnology & Pharmaceutical Companies Research & Academic Institutions Others

Tumor Transcriptomics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tumor Transcriptomics Market.

Available Customizations:

Global Tumor Transcriptomics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tumor Transcriptomics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others)
    • 5.2.2. By Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Others)
    • 5.2.3. By Product (Consumables, Instrument, Software & Services)
    • 5.2.4. By Application (Diagnostics and Disease Profiling, Drug Discovery, Others)
    • 5.2.5. By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Others) By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Tumor Type
    • 5.3.2. By Technology
    • 5.3.3. By Product
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. Asia Pacific Tumor Transcriptomics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Tumor Type
    • 6.2.2. By Technology
    • 6.2.3. By Product
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Tumor Transcriptomics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Tumor Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. India Tumor Transcriptomics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Tumor Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Japan Tumor Transcriptomics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Tumor Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User
    • 6.3.4. South Korea Tumor Transcriptomics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Tumor Type
        • 6.3.4.2.2. By Technology
        • 6.3.4.2.3. By Product
        • 6.3.4.2.4. By Application
        • 6.3.4.2.5. By End User
    • 6.3.5. Australia Tumor Transcriptomics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Tumor Type
        • 6.3.5.2.2. By Technology
        • 6.3.5.2.3. By Product
        • 6.3.5.2.4. By Application
        • 6.3.5.2.5. By End User

7. Europe Tumor Transcriptomics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tumor Type
    • 7.2.2. By Technology
    • 7.2.3. By Product
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Tumor Transcriptomics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tumor Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Germany Tumor Transcriptomics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tumor Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Tumor Transcriptomics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tumor Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Tumor Transcriptomics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Tumor Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Tumor Transcriptomics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Tumor Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. North America Tumor Transcriptomics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tumor Type
    • 8.2.2. By Technology
    • 8.2.3. By Product
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United Kingdom Tumor Transcriptomics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tumor Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Canada Tumor Transcriptomics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tumor Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Mexico Tumor Transcriptomics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tumor Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User

9. South America Tumor Transcriptomics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tumor Type
    • 9.2.2. By Technology
    • 9.2.3. By Product
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tumor Transcriptomics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tumor Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Tumor Transcriptomics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tumor Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Tumor Transcriptomics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tumor Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Tumor Transcriptomics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tumor Type
    • 10.2.2. By Technology
    • 10.2.3. By Product
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Tumor Transcriptomics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tumor Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Tumor Transcriptomics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tumor Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Tumor Transcriptomics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tumor Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User
    • 10.3.4. Egypt Tumor Transcriptomics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Tumor Type
        • 10.3.4.2.2. By Technology
        • 10.3.4.2.3. By Product
        • 10.3.4.2.4. By Application
        • 10.3.4.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Tumor Transcriptomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Thermo Fischer Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Caris Life Sciences
  • 15.3. Illumina, Inc.
  • 15.4. NanoString Technologies, Inc.
  • 15.5. 10x Genomics, Inc.
  • 15.6. Agilent Technologies, Inc.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. F. Hoffmann-La Roche AG
  • 15.9. Standard BioTools Inc.
  • 15.10. Pacific Biosciences of California, Inc

16. Strategic Recommendations

17. About Us & Disclaimer